CTSO - CytoSorbents Corp Stock Price, Fair Value and News

0.96USD+0.09 (+10.34%)Delayed

Market Summary

USD0.96+0.09

Delayed

10.34%

CTSO Stock Price

View Fullscreen

CTSO RSI Chart

CTSO Valuation

Market Cap

52.1M

Price/Earnings (Trailing)

-1.89

Price/Sales (Trailing)

1.42

EV/EBITDA

-1.68

Price/Free Cashflow

-2.22

CTSO Price/Sales (Trailing)

CTSO Profitability

EBT Margin

-77.29%

Return on Equity

-145.5%

Return on Assets

-58.51%

Free Cashflow Yield

-44.98%

CTSO Fundamentals

CTSO Revenue

Revenue (TTM)

36.7M

Rev. Growth (Yr)

3.56%

Rev. Growth (Qtr)

12.9%

CTSO Earnings

Earnings (TTM)

-27.5M

Earnings Growth (Yr)

13.21%

Earnings Growth (Qtr)

-8.96%

Breaking Down CTSO Revenue

Last 7 days

5.5%

Last 30 days

21.5%

Last 90 days

-4.9%

Trailing 12 Months

-73.2%

How does CTSO drawdown profile look like?

CTSO Financial Health

Current Ratio

1.49

Debt/Equity

0.1

Debt/Cashflow

-12.12

CTSO Investor Care

Shares Dilution (1Y)

23.55%

Diluted EPS (TTM)

-0.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	36.7M	0	0	0
2023	35.4M	36.4M	37.1M	36.3M
2022	41.3M	37.7M	36.1M	34.7M
2021	42.9M	45.1M	44.3M	43.2M
2020	28.5M	32.0M	36.5M	41.0M
2019	22.8M	23.2M	23.6M	24.9M
2018	17.0M	19.2M	21.1M	22.5M
2017	10.8M	12.2M	13.6M	15.2M
2016	5.9M	7.1M	8.2M	9.5M
2015	3.8M	3.7M	3.9M	4.8M
2014	3.1M	3.8M	4.1M	4.1M
2013	1.7M	1.9M	2.2M	2.4M
2012	366.9K	697.8K	1.0M	1.4M
2011	216.9K	126.5K	0	36.1K
2010	0	0	0	307.3K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of CytoSorbents Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	deliargyris efthymios	acquired	-	-	61,000	chief medical officer
Apr 02, 2024	capponi vincent	acquired	-	-	81,000	president and coo
Apr 02, 2024	chan phillip p.	acquired	-	-	96,000	chief executive officer
Apr 02, 2024	bloch kathleen p.	acquired	-	-	65,000	chief financial officer
Dec 13, 2023	bator michael g.	bought	50,000	1.33	37,594	-
Dec 13, 2023	sobel alan d.	bought	30,000	1.33	22,557	-
Dec 13, 2023	capponi vincent	bought	25,000	1.33	18,797	president & coo
Dec 13, 2023	jones edward raymond	bought	10,000	1.33	7,519	-
Dec 13, 2023	deliargyris efthymios	bought	30,000	1.33	22,557	chief medical officer
Dec 13, 2023	kim jiny	bought	10,000	1.33	7,519	-

Which funds bought or sold CTSO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	added	61.27	219	795	-%
May 16, 2024	JANE STREET GROUP, LLC	new	-	44,322	44,322	-%
May 16, 2024	AVENIR CORP	added	3.98	-372,995	3,014,060	0.26%
May 15, 2024	BRADLEY FOSTER & SARGENT INC/CT	unchanged	-	-1,600	9,500	-%
May 15, 2024	Granahan Investment Management, LLC	reduced	-15.85	-1,123,550	2,892,590	0.10%
May 15, 2024	Royal Bank of Canada	added	17.72	-	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-20.57	-16,041	34,051	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	30.37	791	7,623	-%
May 15, 2024	Regal Investment Advisors LLC	reduced	-74.88	-39,931	10,934	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-44.75	-39,073	35,053	-%

Are Funds Buying or Selling CTSO?

Are funds buying CTSO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CTSO

No. of Funds

Unveiling CytoSorbents Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	granahan investment management, llc	6.93%	3,618,143	SC 13G
Feb 14, 2024	avenir corp	6.87%	3,051,402	SC 13G
Jan 08, 2024	skylands capital, llc	7.3%	3,254,213	SC 13G
Feb 14, 2023	avenir corp	5.61%	2,447,089	SC 13G/A
Feb 09, 2023	vanguard group inc	4.48%	1,956,828	SC 13G/A
Feb 07, 2023	skylands capital, llc	5.8%	2,542,091	SC 13G
Jul 08, 2022	blackrock inc.	1.7%	744,958	SC 13G
Jun 28, 2022	avenir corp	4.95%	2,156,833	SC 13G/A
Apr 25, 2022	avenir corp	5.00%	2,177,146	SC 13G
Feb 09, 2022	vanguard group inc	5.08%	2,209,165	SC 13G/A

Recent SEC filings of CytoSorbents Corp

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 06, 2024	8-K	Current Report
Apr 19, 2024	ARS	ARS
Apr 19, 2024	DEF 14A	DEF 14A
Apr 19, 2024	DEFA14A	DEFA14A
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading

Peers (Alternatives to CytoSorbents Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

CytoSorbents Corp News

Latest updates

CytoSorbents Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	12.9%	9,786,292	8,668,215	8,810,847	9,420,821	9,449,496	9,390,474	8,111,353	8,495,558	8,691,424	10,782,195	9,760,416	12,024,069	10,598,847	11,955,776	10,546,612	9,794,903	8,707,310	7,430,311	6,095,007	6,232,526	5,191,629
Gross Profit	23.7%	6,570,579	5,311,280	5,606,866	6,018,550	5,455,327	5,757,036	3,617,377	4,944,856	6,413,788	7,659,452	7,297,470	9,313,852	7,847,403	9,428,358	7,656,230	6,545,136	6,322,468	5,335,621	4,398,733	4,398,160	3,453,040
Operating Expenses	-21.7%	11,496,097	14,686,104	12,957,064	12,577,787	13,346,923	12,113,392	12,634,715	13,301,906	14,204,923	17,221,274	12,703,470	14,238,585	10,699,594	12,062,623	9,615,879	9,842,803	8,801,222	10,766,949	10,026,279	8,028,157	7,738,233
S&GA Expenses	-7.6%	8,567,200	9,275,047	8,104,392	7,723,952	8,463,275	7,952,892	8,735,048	8,439,367	9,160,823	10,442,710	7,776,575	9,821,490	7,709,703	8,273,530	7,282,357	6,590,903	6,316,934	6,633,194	6,107,877	4,506,516	4,758,084
R&D Expenses	-45.1%	2,248,191	4,096,499	3,749,197	3,668,804	4,214,415	3,401,931	3,290,149	4,183,462	4,243,365	6,137,358	4,262,206	3,699,314	2,282,052	2,685,781	1,753,455	2,406,039	1,965,286	3,558,456	3,185,105	2,929,603	2,418,633
EBITDA Margin	5.4%	-0.72	-0.76	-0.62	-0.72	-0.88	-0.95	-1.14	-0.94	-0.71	-0.56	-0.36	-0.23	-	-	-	-	-	-	-	-	-
Interest Expenses	97.3%	199,418	101,093	102,241	102,222	71,112	-	-	-	-	-	-	-	-	243,790	298,029	266,949	318,879	327,004	274,204	230,652	227,681
Income Taxes	-	-	-	-	-	-	-1,092,585	-	-	-	-736,003	-	-	-	-1,127,074	-	-	-	-1,092,446	-	-	-
Earnings Before Taxes	4.4%	-6,357,861	-6,648,646	-9,193,520	-6,153,084	-7,325,883	-1,858,711	-12,200,837	-10,879,222	-8,966,398	-10,043,015	-6,406,285	-4,677,530	-4,167,821	-1,804,798	-839,729	-2,866,956	-3,452,779	-5,041,797	-6,885,061	-3,547,405	-4,883,827
EBT Margin	4.2%	-0.77	-0.81	-0.66	-0.76	-0.91	-0.98	-1.17	-0.96	-0.73	-0.59	-0.38	-0.25	-	-	-	-	-	-	-	-	-
Net Income	-9.0%	-6,357,861	-5,834,907	-9,193,520	-6,153,084	-7,325,883	-766,128	-12,200,837	-10,879,222	-8,966,398	-9,307,012	-6,406,285	-4,677,530	-4,167,821	-677,724	-839,729	-2,866,956	-3,452,779	-3,949,351	-6,885,061	-3,547,405	-4,883,827
Net Income Margin	4.3%	-0.75	-0.78	-0.63	-0.73	-0.88	-0.95	-1.15	-0.94	-0.71	-0.57	-0.36	-0.23	-	-	-	-	-	-	-	-	-
Free Cashflow	25.0%	-4,874,950	-6,502,908	-5,348,625	-6,723,838	-3,617,880	-5,553,764	-7,374,557	-12,563,917	-8,829,409	-7,024,026	-5,025,085	-2,824,861	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-11.6%	47.00	53.00	48.00	52.00	57.00	63.00	62.00	71.00	83.00	90.00	95.00	98.00	87.00	90.00	104	49.00	44.00	27.00	29.00	28.00	31.00
Current Assets	-22.2%	20.00	26.00	19.00	24.00	28.00	34.00	32.00	42.00	56.00	64.00	73.00	77.00	80.00	82.00	97.00	42.00	38.00	21.00	22.00	22.00	25.00
Cash Equivalents	-28.6%	10.00	14.00	8.00	13.00	19.00	22.00	24.00	32.00	45.00	54.00	61.00	66.00	68.00	71.00	88.00	35.00	26.00	12.00	16.00	16.00	20.00
Inventory	1.6%	4.00	4.00	3.00	2.00	2.00	3.00	4.00	5.00	5.00	5.00	5.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00
Net PPE	-3.1%	10.00	10.00	10.00	11.00	11.00	11.00	11.00	10.00	8.00	5.00	4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Liabilities	-6.1%	28.00	30.00	29.00	28.00	29.00	28.00	23.00	24.00	28.00	27.00	24.00	24.00	10.00	11.00	24.00	25.00	23.00	24.00	22.00	17.00	16.00
Current Liabilities	-7.7%	13.00	15.00	12.00	10.00	10.00	10.00	10.00	11.00	15.00	14.00	11.00	11.00	10.00	10.00	17.00	16.00	11.00	10.00	9.00	7.00	7.00
Long Term Debt	-24.2%	2.00	3.00	4.00	5.00	-	5.00	-	-	-	-	-	-	-	-	6.00	8.00	11.00	13.00	12.00	9.00	8.00
LT Debt, Current	0%	3.00	3.00	1.00	-	-	-	-	-	-	-	-	-	-	-	9.00	7.00	4.00	2.00	3.00	1.00	2.00
LT Debt, Non Current	-100.0%	-	3.00	4.00	5.00	-	5.00	-	-	-	-	-	-	-	-	6.00	8.00	11.00	13.00	12.00	9.00	8.00
Shareholder's Equity	-18.7%	19.00	23.00	19.00	24.00	29.00	35.00	39.00	48.00	55.00	63.00	71.00	74.00	77.00	79.00	80.00	24.00	21.00	3.00	7.00	12.00	15.00
Retained Earnings	-2.3%	-288	-282	-276	-267	-261	-254	-253	-241	-230	-221	-211	-205	-200	-196	-195	-195	-192	-188	-184	-177	-174
Additional Paid-In Capital	0.3%	306	305	292	290	289	287	286	285	284	283	282	281	279	278	277	219	212	192	190	189	189
Shares Outstanding	0.1%	54.00	54.00	44.00	44.00	44.00	44.00	44.00	44.00	43.00	43.00	43.00	43.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	144	-	61.00	-	-	-	-	-	263	-	-	-	306	-	-	-	179	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	24.6%	-4,829	-6,407	-5,206	-6,933	-3,108	-5,340	-6,734	-8,039	-8,119	-5,491	-4,133	-2,036	-2,344	-1,057	-3,284	1,938	-3,209	-4,124	-5,208	-3,188	-4,237
Share Based Compensation	-12.9%	734	843	1,086	570	830	869	1,005	761	787	797	999	1,558	667	650	1,088	1,046	729	491	802	145	228
Cashflow From Investing	6.6%	-127	-135	-257	140	-682	-206	-716	-4,685	-847	-1,672	-1,017	-984	-606	-266	-404	-497	-508	-403	-315	-327	-474
Cashflow From Financing	-104.7%	-571	12,210	648	931	684	5,000	-	-	-40.36	-80.92	590	130	77.00	-15,147	56,381	7,233	17,882	773	5,220	180	2,005

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CTSO Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 9,786,292	$ 9,449,496
Cost of revenue	3,215,713	3,994,169
Gross profit	6,570,579	5,455,327
Operating expenses:
Research and development	2,248,191	4,214,415
Legal, financial and other consulting	680,706	669,233
Selling, general and administrative	8,567,200	8,463,275
Total operating expenses	11,496,097	13,346,923
Loss from operations	(4,925,518)	(7,891,596)
Other income (expense):
Interest income (expense), net	(6,653)	(63,170)
Miscellaneous income/(expense)		(31,798)
Gain (Loss) on foreign currency transactions	(1,425,690)	660,681
Total other income (expense), net	(1,432,343)	565,713
Loss before benefit from income taxes	(6,357,861)	(7,325,883)
Net loss attributable to common stockholders	$ (6,357,861)	$ (7,325,883)
Basic net loss per common share	$ (0.12)	$ (0.17)
Diluted net loss per common share	$ (0.12)	$ (0.17)
Weighted average number of shares of common stock outstanding, basic	54,262,790	43,676,435
Weighted average number of shares of common stock outstanding, diluted	54,262,790	43,676,435
Comprehensive loss:
Net loss	$ (6,357,861)	$ (7,325,883)
Other comprehensive income/(loss):
Foreign currency translation adjustment	1,223,175	(608,208)
Comprehensive loss	(5,134,686)	(7,934,091)
Total product sales
Revenue:
Total revenue	8,989,520	7,910,039
CytoSorb sales
Revenue:
Total revenue	8,964,790	7,906,269
Other product sales
Revenue:
Total revenue	24,730	3,770
Grant income
Revenue:
Total revenue	$ 796,772	$ 1,539,457

CTSO Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 8,608,380	$ 14,131,137
Grants and accounts receivable, net of allowances of $48,229 and $49,663 as of March 31, 2024 and December 31, 2023, respectively	6,765,290	6,057,072
Inventories	3,738,767	3,680,129
Prepaid expenses and other current assets	880,363	1,834,485
Total current assets	19,992,800	25,702,823
Property and equipment, net	9,748,651	10,056,354
Restricted cash	1,483,958	1,483,958
Right-of-use assets	11,925,299	12,058,896
Other assets	3,919,897	3,958,603
Total Assets	47,070,605	53,260,634
Current Liabilities:
Accounts payable	2,399,421	3,802,170
Lease liability - current portion	392,617	373,636
Current maturities of long-term debt	2,500,000	2,500,000
Accrued expenses and other current liabilities	8,132,063	7,870,149
Total current liabilities	13,424,101	14,545,955
Lease liability, net of current portion	12,790,008	12,896,659
Long-term debt net of current maturities	1,928,571	2,542,857
Total Liabilities	28,142,680	29,985,471
Commitments and Contingencies (Note 6)
Stockholders' Equity:
Preferred Stock, Par Value $0.001, 5,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common Stock, Par Value $0.001, 100,000,000 shares authorized; 54,293,555 and 54,240,265 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	54,294	54,240
Additional paid-in capital	305,984,268	305,196,874
Accumulated other comprehensive income	1,752,496	529,321
Accumulated deficit	(288,863,133)	(282,505,272)
Total Stockholders' Equity	18,927,925	23,275,163
Total Liabilities and Stockholders' Equity	$ 47,070,605	$ 53,260,634

About CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

CEO	Dr. Phillip P. Chan M.D., Ph.D.
WEBSITE	cytosorbents.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	198

CytoSorbents Corp Frequently Asked Questions

What is the ticker symbol for CytoSorbents Corp? What does CTSO stand for in stocks?

CTSO is the stock ticker symbol of CytoSorbents Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CytoSorbents Corp (CTSO)?

As of Fri May 17 2024, market cap of CytoSorbents Corp is 52.13 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CTSO stock?

You can check CTSO's fair value in chart for subscribers.

What is the fair value of CTSO stock?

You can check CTSO's fair value in chart for subscribers. The fair value of CytoSorbents Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CytoSorbents Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CTSO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CytoSorbents Corp a good stock to buy?

The fair value guage provides a quick view whether CTSO is over valued or under valued. Whether CytoSorbents Corp is cheap or expensive depends on the assumptions which impact CytoSorbents Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CTSO.

What is CytoSorbents Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CTSO's PE ratio (Price to Earnings) is -1.89 and Price to Sales (PS) ratio is 1.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTSO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CytoSorbents Corp's stock?

In the past 10 years, CytoSorbents Corp has provided -0.138 (multiply by 100 for percentage) rate of return.